Abstract��OBJECTIVE To develop an easy to scale-up preparation process for exenatide-loaded long-acting microspheres, and develop a method that can be used to rapidly evaluate the in vitro release properties of the microspheres. METHODS The primary emulsion could be made by high shear emulsification process combined with high pressure homogenization method , then exenatide-loaded microspheres were prepared by a modified coacervation method. In the coacervation step, static mixer was used for mixing the primary emulsion and the coacervation reagent. RESULTS High pressure homogenization could reduce the size of the primary emulsion to about 200 nm. The encapsulation efficiency of microspheres was greater than 96.8%, and the amount of burst release in 1 h was less than 0.5%. When the scale of microspheres preparation was magnified by five times, the characteristics of the obtained microspheres was the same as the small scale batch. The in vitro release curves showed that the continued release time lasted for nearly 4 weeks after the 17 d lag phase. The drug release rate at 45 ��was as high as 2.5 times of that at 37 ��, with same release curves. CONCLUSION The established preparation process of exenatide-loaded long-acting microspheres, which uses static mixer for mixing the primary emulsion and coacervation reagent, is easy for scaling-up and industrialization. Accelerated test at 45 �� can be used to rapidly evaluate the in vitro release profile of the microspheres.
����ϼ, ������, �ܻ�, ��, ������, ������. �������ij�Ч����Ʊ����ռ������ͷ��о�[J]. �й�ҩѧ��־, 2016, 51(3): 218-223.
FU Jun-xia, WANG Dai-feng, ZHOU Hua, ZOU Jia, ZHOU San-yun, JIANG Chao-jun. Preparation Process and in Vitro Release of Exenatide-Loaded Long-acting Microspheres. Chinese Pharmaceutical Journal, 2016, 51(3): 218-223.
MEIER J J. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus [J]. Nat Rev Endocrinol, 2012, 8(12):728-742.
[3]
PAINTER N A, MORELLO C M, SINGH R F, et al. An evidence-based and practical approach to using BydureonTM in patients with type 2 diabetes[J]. J Am Board Fam Med, 2013,26(2):203-210.
[4]
DEYOUNG M B, MACCONE L, SARIN V, et al. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes [J]. Diabetes Technol Ther,2011, 13(11):1145-1154.
[5]
XUAN J M, GAO J, HUANG J B, et al. Preparation of sustained- release microspheres containing exenatide and their in vitro release [J]. Acad J Sec Mil Med Univ (�ڶ���ҽ��ѧѧ��), 2011, 32(7):772-775.
[6]
QI F, WU J, YANG T, et al. Mechanistic studies for monodisperse exenatide-loaded PLGA microspheres prepared by different methods based on SPG membrane emulsification [J]. Acta Biomater, 2014, 10(10):4247-2456.
[7]
WRIGHT S G, CHRISTENSEN T, YEOH T, et al. Polymer based sustained release device:US, 8617613 B2 [P]. 2013-12-31.
[8]
MAC C L, FLORES, CIRINCIONE B, et al, Pharmacokinetics and pharmacodynamics of a new exenatide formulation, exenatide suspension [Z]. 2012:Presentation Number,825.
[9]
JIANG C J, YANG Q M, HU X F, et al. Preparation and in vitro release of novel risperidone-loaded PLGA microspheres [J]. Chin Pharm J (�й�ҩѧ��־), 2011, 46(2):124-127.
[10]
LIU B, DONG Q G, WANG M S, et al. Preparation of long-acting release microspheres of exenatide and studies on their in vivo pharmacodynamics [C]. Beijing:2008:2233-2240.
2016, Vol. 51 
